ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Immunosuppressive antibody therapy has been available since the 1960s, but it is only recently that such therapy has been used more widely. A number of exciting new antibody agents are poised to enter the market and it is likely that their use will increase in the near future. The potential role of these agents in the treatment of renal transplant recipients was discussed at the 32nd Annual Midyear Clinical Meeting of the American Society of Health Systems Pharmacists [Atlanta, US; December 1997].

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

In patients with hypercholesterolaemia, lowering cholesterol levels using HMG CoA reductase inhibitors (statins) can reduce the risk of fatal and nonfatal myocardial infarction (MI) and death from heart disease, Of the 5 HMG CoA reductase inhibitors currently available on the US market, the newest of these, atorvastatin, is the most potent in terms of lowering cholesterol and triglyceride levels. There is also growing evidence that atorvastatin is the most cost effective of these lipid-lowering agents. At the Association for Pharmacoeconomics and Outcomes Research (APOR) Lipid Conference [Florida, US; November 1997], the results of several pharmacoeconomic studies, including a pharmacoeconomic assessment of the CURVES*trial, showed atorvastatin to be more cost effective than other HMG CoA reductase inhibitors.

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS